RIP
CORT icon

Reliant Investment Partners’s Corcept Therapeutics CORT Stock Holding History

Reliant Investment Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,207
Closed -$459K – 112
2025
Q3 		$459K Hold
5,207
– – 0.36% 64
2025
Q2 		$382K Hold
5,207
– – 0.33% 78
2025
Q1 		$595K Sell
5,207
-45
-0.9% -$2.74K 0.61% 38
2024
Q4 		$265K Buy
+5,252
New +$275K 0.23% 96

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Reliant Investment Partners's CORT Position: Q4 2025 in Review

Reliant Investment Partners sold out of Corcept Therapeutics (CORT) in Q4 2025, closing a stake of 5,207 shares — an estimated $459K sold.

Reliant Investment Partners first reported a position in CORT in Q4 2024 and held it in 4 quarters. The position peaked at $595K in Q1 2025. 389 funds tracked by Wall St. Rank hold CORT as of Q4 2025.

  • Reliant Investment Partners reported no remaining Corcept Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Reliant Investment Partners sold 5,207 Corcept Therapeutics shares in Q4 2025, an estimated $459K.
  • Reliant Investment Partners first reported a position in Corcept Therapeutics in Q4 2024 and held it in 4 quarters.
  • Reliant Investment Partners's Corcept Therapeutics position peaked at $595K in Q1 2025.
  • 389 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2025.

Based on Reliant Investment Partners's 13F filing for Q4 2025, filed 6 Feb 2026.